Integra LifeSciences (IART) Stock Forecast & Price Target

$19.87

+0.11 (+0.56%)

(As of 10/18/2024 08:52 PM ET)

Integra LifeSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 9 Analyst Ratings

Sell
3

Hold
4

Buy
2

Based on 9 Wall Street analysts who have issued ratings for Integra LifeSciences in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 9 analysts, 3 have given a sell rating, 4 have given a hold rating, and 2 have given a buy rating for IART.

Consensus Price Target

$26.50
33.37% Upside

According to the 9 analysts' twelve-month price targets for Integra LifeSciences, the average price target is $26.50. The highest price target for IART is $50.00, while the lowest price target for IART is $16.00. The average price target represents a forecasted upside of 33.37% from the current price of $19.87.

IART Analyst Ratings Over Time

Type	Current Forecast 10/22/23 to 10/21/24	1 Month Ago 9/22/23 to 9/21/24	3 Months Ago 7/24/23 to 7/23/24	1 Year Ago 10/22/22 to 10/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	3 Sell rating(s)	4 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$26.50	$28.63	$32.86	$47.29
Forecasted Upside	33.37% Upside	64.51% Upside	4.74% Upside	24.63% Upside
Consensus Rating	Reduce	Reduce	Hold	Reduce

[Urgent] Starlink Set For The Largest IPO In History? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

IART Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IART Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Integra LifeSciences Stock vs. The Competition

Type	Integra LifeSciences	Medical Companies	S&P 500
Consensus Rating Score	1.89	2.79	2.50
Consensus Rating	Reduce	Moderate Buy	Hold
Predicted Upside	33.37% Upside	13,587.63% Upside	6.20% Upside
News Sentiment Rating	Neutral News See Recent IART News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/14/2024	Truist Financial 2 of 5 stars		Lower Target	Hold ➝ Hold	$26.00 ➝ $21.00	+10.64%
10/7/2024	Bank of America 4 of 5 stars		Lower Target	Underperform ➝ Underperform	$26.00 ➝ $18.00	+4.23%
10/7/2024	BTIG Research 2 of 5 stars	R. Zimmerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral
10/1/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sell ➝ Sell	$20.00 ➝ $16.00	-9.09%
7/30/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$40.00 ➝ $35.00	+37.09%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$24.00 ➝ $27.00	-9.12%
[Urgent] Starlink Set For The Largest IPO In History? (Ad) He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO. Click here now for the urgent details on this hidden play.
5/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
5/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$45.00 ➝ $25.00	+8.04%
11/14/2023	CL King Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+36.61%
7/12/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$58.00 ➝ $53.00	+28.33%
6/26/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$55.00 ➝ $44.00	+11.25%
6/8/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
5/24/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$56.00 ➝ $43.00	+6.23%
5/23/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:15 AM ET.

IART Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Integra LifeSciences is $26.50, with a high forecast of $50.00 and a low forecast of $16.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" IART shares.
: According to analysts, Integra LifeSciences's stock has a predicted upside of 33.37% based on their 12-month stock forecasts.
: Over the previous 90 days, Integra LifeSciences's stock had 2 downgrades and 1 upgrade by analysts.
: Integra LifeSciences has been rated by research analysts at Bank of America, BTIG Research, Citigroup, JMP Securities, and Truist Financial in the past 90 days.
: Analysts like Integra LifeSciences less than other "medical" companies. The consensus rating for Integra LifeSciences is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IART compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Have you heard of Donald Trump’s Project Crypto? (Ad)

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Learn More Here

This page (NASDAQ:IART) was last updated on 10/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Integra LifeSciences (IART) Stock Forecast & Price Target